The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate

Gunar K. Zagars

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Purpose: The aim of this study was to define criteria for interpreting a single serum prostate-specific antigen (PSA) level measured at 6 months to 5 years after definitive radiotherapy for prostate cancer. Methods and Materials: Two hundred and ninety-two patients with Stages A2 to C prostate cancer treated with radiotherapy only and followed up with multiple PSA determinations were studied. The patients were stratified into PSA strata based on the highest PSA level recroved for each patient at 6 to 60 months after treatment. The PSA strata and the number of patients in each were: (a) PSA ≤ 1 ng/ml, 114 patients; (b) PSA > 1, but ≤ 2 ng/ml, 60 patients; (c) PSA > 2, but ≤ 4 ng/ml, 48 patients; (d) PSA > 4, but ≤ 10 ng/ml, 47 patients; (e) PSA > 10 ng/ml, 23 patients. Desease outcome specified as relapse, rising PSA profile or both was evaluated in each PSA stratum. Results: The actuarial 3-year incidence of relapse in each PSA stratum was: (a) 5%; (b) 0%; (c) 12%; (d) 31%; and, (e) 84%. If the occurrence of a rising PSA profile was included as an endpoint then the incidence of relapse or rising PSA at 3 years in each PSA stratum was: (a) 5%; (b) 14%; (c) 45%; (d) 84%; and, (e) 100%. Patients with the a highest late PSA value ≤ 4 ng/ml had a 20% incidence of relapse or rising PSA at 4 years; patients with a highest late PSA value > 4 ng/ml had a 90% incidence of relapse or rising PSA at 3 years. Conclusion: A PSA level of 4 ng/ml is a good criterion for prognostication of a single PSA level obtained at 6 months to 5 years after radiotherapy. Patients whose PSA level in that time interval exceeds 4 ng/ml have a poor outcome.

Original languageEnglish (US)
Pages (from-to)39-45
Number of pages7
JournalInternational journal of radiation oncology, biology, physics
Volume27
Issue number1
DOIs
StatePublished - Sep 1 1993

Keywords

  • Prostate cancer
  • Prostate-specific antigen
  • Radiation therapy

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate'. Together they form a unique fingerprint.

  • Cite this